Whitehawk Therapeutics (WHWK) Research & Development (2016 - 2026)

Whitehawk Therapeutics (WHWK) has 11 years of Research & Development data on file, last reported at $17.2 million in Q1 2026.

• On a quarterly basis, Research & Development rose 96.09% year-over-year to $17.2 million in Q1 2026; TTM through Mar 2026 was $99.4 million, a 115.05% increase from a year earlier, with the FY2025 full-year figure at $91.0 million, up 78.25% from the prior year.
• Research & Development for Q1 2026 stood at $17.2 million, down from $19.0 million in the prior quarter.
• Over the last five years, Research & Development for WHWK reached as high as $48.8 million in Q2 2025 and fell as low as $6.8 million in Q1 2022.
• Historically, Research & Development has averaged $14.2 million across 5 years, with a median of $12.8 million in 2023.
• On a YoY basis, Research & Development climbed as much as 272.79% in 2025 and fell as far as 35.35% in 2025.
• Year by year, Research & Development stood at $9.4 million in 2022, then surged by 36.26% to $12.8 million in 2023, then advanced by 12.37% to $14.3 million in 2024, then soared by 32.58% to $19.0 million in 2025, then slipped by 9.41% to $17.2 million in 2026.
• Per Business Quant data, the three most recent Research & Development figures were $17.2 million in Q1 2026, $19.0 million in Q4 2025, and $14.3 million in Q3 2025.